The company amended its disclosure for a supply contract of anti-counterfeiting security products to a Middle Eastern government pharmaceutical security solutions provider.
The contract amount of approximately 1.55 billion KRW represents 29.31% of 2024 consolidated revenue of 5.28 billion KRW, with 50% of payments already received.
Due to the counterparty's trade secret protection request, detailed information remains undisclosed, and the remaining payment is expected by June 30, 2026.
[AI Summary]This contract is a normal operational activity tied to the existing business, with no capital changes or dilution effects. The counterparty is a government-related entity, lending credibility, but the lack of disclosure creates information asymmetry. The impact on short-term stock price is limited; contract execution and future orders will determine price direction.
KOSDAQ Filing Information
[Correction of Description] Conclusion of Single Sale and Supply Contract